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Plasma copper is reportedly increased in pregnancy, infections, and inflammation and decreased in corticosteroid and corticotropin treatment (1 ) . The usual and convenient methods for measurement of metal ions are colorimetry and atomic absorption spectrophotometry (AAS). These methods, however, are not suitable for copper. For example, the molar absorptivity at 480 nm of copper complex with bathocuproine disulfonic acid, the most suitable reagent, is not strong (⑀ ϭ 1.3 ϫ 10 4 ) (2-4 ), and the atomic absorption at 324.7 nm specific to copper is marginal. As a consequence, both methods require 2 mL of serum, although the copper concentration in plasma is fairly high, e.g., 15.7 mol/L (1 g/mL). A more sensitive but selective and convenient method is needed for quantification of small amounts of copper in blood as well as in polluted water, food, and tissues.
Electron spin resonance (ESR) is a very sensitive method that requires only 10 9 spins for detection. We examined the use of ESR for measurement of copper because Cu 2ϩ is paramagnetic, and thus can be measured by ESR, although Cu ϩ is diamagnetic. We confirmed the results of a previous report that diethyldithiocarbamate (DDC) reacts with Cu 2ϩ at pH 0 -10 (5 ). The Cu 2ϩ -DDC complex could be extracted with most organic solvents at these pHs (5, 6 ) . We found that the addition of Na 2 SO 4 facilitated the extraction of the complex with 1-butanol. As shown in Fig. 1A (spectrum a), Cu 2ϩ -DDC in 1-butanol shows a characteristic fourline ESR spectrum with hyperfine splitting of 80 gauss and a splitting factor (g) of 2.047. The height of the peak indicated by the arrow at the highest magnetic field of 3350 gauss was used for the quantification of copper.
To liberate copper from bound protein in plasma, the pH of the solution should be adjusted to Ͻ5 (7 ) . To determine suitable acids, we added 0.15 mL of 1 mol/L solutions of several acids to 1 mL of plasma.
The addition of HNO 3 , HClO 4 , or H 3 PO 4 gave the same amounts of copper obtained from wet-ashed plasma, but the addition of HCl, HCOOH, CH 3 COOH, or H 2 SO 4 gave only ϳ80%. In the present work, HNO 3 was used to acidify plasma. The final pH was 3.3 or 1.5 after the addition of 0.1 or 0.15 mL of 1 mol/L HNO 3 , respectively, to 1 mL of plasma. DDC can react with all Cu 2ϩ when the concentration of DDC is high enough (8 ) . For the determination of copper concentration in tissue, tissue was wet-ashed with concentrated HNO 3 and the solution was diluted until its pH was Ͼ0.
Among dozens of chelators, DDC is the one that binds Cu 2ϩ in the presence of ceruloplasmin (7 ) . We confirmed that the present method could be used for plasma containing bilirubin, ascorbic acid, or anticoagulants such as EDTA, oxalic acid, succinic acid, and heparin, although these substances made colorimetric assay of copper difficult (4, 9 ) .
ESR measurements were performed on a JEOL JES-FE2XG ESR spectrometer. For comparisons with ESR, copper was also measured by AAS using a Shimadzu AA-6200 flame atomic absorption instrument. A centrifuge with maximum 6000g and a vortex-type mixer were also used. Polypropylene tubes (0.5 mL) were obtained from Eppendorf, pipettes and 0.1-10 L pipette tips were from Gilson, and 20-L quartz hematocrit capillaries [60 mm long ϫ 0.8 mm (o.d.)] were from Drummond Scientific. We could not use glass or plastic hematocrit capillaries because of the strong ESR signals produced by impurities. To seal the capillaries, we used a vinyl plastic putty (CRITOSEAL; Oxford Labware). All chemicals were of atomic absorption grade or biochemical grade from Wako Pure Chemical Ltd. The ultra-pure water (specific resistance, 18 megaohms ⅐ cm) was used. All glassware and plastics were soaked in concentrated HNO 3 or 0.3 mol/L HNO 3 , respectively, overnight and rinsed Ͼ10 times with ultra-pure water.
On the basis of these findings and using materials and instruments mentioned above, we used the following procedure to prepare plasma and tissue samples for quantification of copper: (a) 5 L of plasma (or 5 L of copper calibration solution) was placed in a small tube that could tolerate acid at pH 0 as well as centrifugation at 6000g; (b) 0.75 L of 1 mol/L HNO 3 was added to the tube and mixed for 10 s in a vortex-type mixer; (c) 0.75 L of an aqueous solution containing 100 g/L DDC was added and mixed for 10 s (DDC solution stored at 4°C in the dark is stable for 4 weeks); (d) 6 l of 1-butanol was added and mixed for 10 s; (e) ϳ3 mg of Na 2 SO 4 was added and mixed for 30 s; (f) the tube was centrifuged at 6000g for 2 min; (g) 5 L of the top (1-butanol) layer was removed and placed Clinical Chemistry 47, No. 10, 2001 in a hematocrit capillary, and the top and bottom of the capillary were sealed with putty; (h) the capillary was inserted in a quartz ESR cell and placed in the ESR cavity.
For tissues, we confirmed that the pH of wet-ashed tissue solution was Ͻ0 and added DDC, 1-butanol, and Na 2 SO 4 as in the case of plasma.
The ESR conditions were as follows: spectrometer setting, 3300 gauss; sweep range, 1000 gauss; sweep time, 8 min; response time, 1 s; microwave power, 6 mW; modulation width, 20 gauss. Measure the height of the peak at 3350 gauss. It takes ϳ30 s to measure the peak.
It took ϳ5 min for the quantification of one sample when we used the preparation steps listed above. Because some processes, such as mixing and centrifugation, can be performed simultaneously for multiple samples, it took only 1 h to process 24 samples (e.g., 4 calibrators and 20 specimens).
Tracing b in Fig. 1A was obtained from 5 L of plasma taken from a Wistar strain rat treated with 1 g Diquat/kg diet for 14 days, and tracing c was obtained from plasma from control rat without Diquat treatment. Tracing d in Fig. 1A represents 0.3 mg of wet kidney taken from a spontaneous hypertensive od-rat (SHR-od), and tracing e represents wet kidney from a normotensive od-rat (ODSrat). Because od-rats cannot synthesize vitamin C, the rats represented by tracings d and e received adequate amounts of vitamin C. Human plasma shows a spectrum similar to those in Fig. 1A , tracings b and c.
The precision was evaluated by 10 analyses of two plasma samples. The within-run difference was Ͻ5%. The recovery of added copper (7.9, 15.7, 23.6, and 31.4 mol/L) from plasma with an endogenous copper concentration of 15.7 mol/L was Ͼ95%. Human plasma from 50 healthy males 20 -60 years of age and 50 healthy females 20 -60 years of age was examined by two methods, ESR and AAS. The mean value (SD) for men was 14.8 Ϯ 2.2 mol/L, and that for women was 17.3 Ϯ 2.7 mol/L, in good agreement with reported values (4, 9, 10 ) . The regression equation for the present method (y) and AAS (x) measured by AAS was: y ϭ 0.94x ϩ 1.0 (r ϭ 0.97; Fig. 1B) .
Most metals can form complexes with DDC, and most of the complexes are extracted with 1-butanol. Some complexes are diamagnetic and some are paramagnetic. However, the peaks that interfere with copper are not observed in plasma, kidney, liver, heart, lung, and spleen, although Fig. 1A indicates only the results for plasma and kidney. Because ESR is a nondestructive method, we might be able to use the extract in the future for assays of other metals as well as for copper.
Although most organic solvents can extract Cu 2ϩ -DDC complex, 1-butanol is used because alcohols such as butanol and cyclohexanol do not dissolve the putty used for sealing the capillary. 1-Butanol and cyclohexanol saturated with putty do not show ESR signals attributable to the putty. When measuring the signal for the Cu 2ϩ - DDC complex in a capillary, it is better to adjust the capillary so that the putty remains outside the ESR cavity: although the putty signals do not interfere with the Cu 2ϩ -DDC complex signals, they do change the baseline. Cu 2ϩ -DDC complex in 1-butanol is quite stable and is not affected by exposure to room light for a few hours. The peak height of the Cu 2ϩ -DDC complex remained unchanged for 3 days when the complex was kept in the dark, and the volume of 1-butanol was maintained.
In the present method, Cu 2ϩ -DDC complex is placed in a hematocrit capillary first and the capillary is placed in the ESR cell; therefore, when a different sample is to be measured, only the capillaries are changed. This is very convenient because we do not need to wash the ESR cell between samples. The wall of the quartz capillary and the quartz wall of the ESR cell, however, have a weak signal at 3270 guass, as indicated by the arrow in Fig. 1A , part e, and may contain some substances that shift the baseline from a lower magnetic field to a higher magnetic field as observed in Fig. 1A . Therefore, the limit of detection is 15.7 nmol of copper (1 ng of copper). The signal of Fig. 1 , part d, corresponds to 3 ng of copper. The sensitivity may improve when capillaries and ESR cells that do not have signals near the signal of copper become available. For the quantification of copper in plasma, flame AAS and colorimetry require 2 mL of plasma, but graphite furnace AAS and inductively coupled plasma-optical emission spectrometry require 5 L of plasma (11 ), which is the same amount as the present method.
In ESR measurements, samples with higher concentrations can be measured without dilution, either by decreasing the gain from 10 4 to 1 or by decreasing the microwave power from 6 mW to nearly 0 mW. A small bench-top ESR instrument can be obtained at a cost comparable to that of an atomic absorption spectrometer. Estrogen (1-5 ) may increase hepatic production of thyroxine-binding globulin (TBG) and decrease TBG clearance (6 ), thus increasing serum total thyroxine (tT 4 ) (3, 4 ) and, to a lesser extent, total triiodothyronine (tT 3 ) (3, 4 ) . As a result, increased tT 4 and tT 3 are seen in states of excessive estrogen and/or progestin, such as pregnancy, estrogen replacement therapy (HRT) (5 ), and oral contraceptive usage (1 ) . This phenomenon may cause problems in clinical diagnoses when tT 4 or tT 3 is used for these patients. On the other hand, estrogen has been shown to increase thyroid-stimulating hormone (TSH) and to decrease free thyroxine (fT 4 ) through a mild inhibitory effect on the thyroid gland (4 ) . Compound that are analogs of estrogens, such as tamoxifen, have been shown to increase TSH without decreasing fT 4 (7, 8 ) . Recently, a new category of therapeutic agents, collectively termed selective estrogen receptor modulators (SERMs), has been developed to treat patients with postmenopausal osteoporosis (9 ) . Raloxifene is one SERM. It decreases bone resorption (9, 10 ) and serum LDL-cholesterol (9, 11, 12 ) , but it does not stimulate breast (13 ) or endometrium (14 ) at the recommended dosage of 60 mg daily. This agent is becoming one of the first-line pharmaceutical agents for postmenopausal osteoporosis and is currently administered to a large number of patients. However, the effect of long-term raloxifene usage on TBG, T 3 uptake, tT 3 , tT 4 , fT 4 , and TSH has not been well documented. To investigate whether raloxifene causes changes in serum concentrations of these markers, we compared the effects of 1 year of treatment with either raloxifene or combined continuous estrogen and progesterone (CCEP) on the thyroid function test profiles, estradiol 2 (E2), and folliclestimulating hormone (FSH).
Effects of Long
We studied 60 euthyroid postmenopausal women (age range, 40 -75 years) with relatively low bone mineral density. The t-score, using the mean and SD of healthy premenopausal Taiwanese women as reference (15 ), ranged from ϩ1 to Ϫ2.49. These 60 women were divided into two groups in a double-blind, randomized fashion.
